EVerZom

EVerZom is a pioneering, privately-held biotech developing exosome therapeutics for regenerative medicine. The company has built an integrated, patented platform covering cell sourcing, exosome generation, loading, and formulation, enabling a pipeline led by programs for Crohn's fistula and liver/kidney regeneration, currently in preclinical development. Backed by non-dilutive funding from the European EIC Accelerator, EVerZom is scaling its manufacturing and advancing towards clinical trials while seeking co-development partnerships to expand into other therapeutic areas.

Proprietary, integrated platform covering the entire exosome therapeutic value chain: cell sourcing, exosome generation, exosome loading, and formulation. Designed for high-yield, scalable, and cost-effective production of therapeutic extracellular vesicles.

EVerZom competes in the fast-growing exosome therapeutics space against other biotechs like Evox Therapeutics, Codiak BioSciences, and Aruna Bio, as well as large pharma companies investing in the modality. Differentiation hinges on its integrated manufacturing platform, IP position, and clinical data in specific regenerative indications.